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Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare immunological disorder caused by unbridled
activation of T cells and macrophages, culminating in a life-threatening cytokine storm. A genetic and acquired
subtype are distinguished, termed primary and secondary HLH, respectively. Clinical manifestations of both forms
are frequently preceded by a viral infection, predominantly with herpesviruses. The exact role of the viral infection
in the development of the hemophagocytic syndrome remains to be further elucidated.
Methods: We utilized a recently developed murine model of cytomegalovirus-associated secondary HLH and
dissected the respective contributions of lytic viral replication and immunopathology in its pathogenesis.
Results: HLH-like disease only developed in cytomegalovirus-susceptible mouse strains unable to clear the virus,
but the severity of symptoms was not correlated to the infectious viral titer. Lytic viral replication and sustained
viremia played an essential part in the pathogenesis since abortive viral infection was insufficient to induce a full-
blown HLH-like syndrome. Nonetheless, a limited set of symptoms, in particular anemia, thrombocytopenia and
elevated levels of soluble CD25, appeared less dependent of the viral replication but rather mediated by the host’s
immune response, as corroborated by immunosuppressive treatment of infected mice with dexamethasone.
Conclusion: Both virus-mediated pathology and immunopathology cooperate in the pathogenesis of full-blown
virus-associated secondary HLH and are closely entangled. A certain level of viremia appears necessary to elicit the
characteristic HLH-like symptoms in the model.
Keywords: Hemophagocytic lymphohistiocytosis, HLH, macrophage activation syndrome, MAS, mouse model,
mouse cytomegalovirus, MCMV, immunopathology, virus-mediated pathology
Background
Hemophagocytic lymphohistiocytosis (HLH) is a severe
and potentially lethal hyperinflammatory syndrome, char-
acterized by persistent high fever, hepatosplenomegaly,
pancytopenia, coagulopathy, hyperferritinemia, hemopha-
gocytosis and a cytokine storm. A primary, inherited form
and a secondary, acquired form can be distinguished [1].
Secondary HLH was first described in adults, in
association with active viral infections, upon which it was
termed a “reactive, virus-associated hemophagocytic
syndrome” [2]. Nowadays, the spectrum of secondary
HLH has expanded to include associations with bacterial,
fungal and parasitic infections, underlying malignancies
and autoimmune or autoinflammatory diseases. Virus-
associated secondary HLH constitutes the largest group of
secondary HLH, accounting for approximately 35% of pa-
tients [3]. Noteworthy, viruses are also frequently impli-
cated in malignancy-associated secondary HLH, either as a
co-trigger of the HLH episode or as the cause of the under-
lying malignancy [4]. Furthermore, clinical manifestations
* Correspondence: patrick.matthys@kuleuven.be
1Laboratory of Immunobiology, Rega Institute, Department of Microbiology
and Immunology, KU Leuven, Leuven, Belgium
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Brisse et al. Virology Journal  (2017) 14:240 
DOI 10.1186/s12985-017-0908-0
of primary HLH are predominantly precipitated by a viral
infection [5]. Several viral agents are capable of triggering
HLH, including parvovirus B19, influenza virus, enterovi-
ruses and adenoviruses, but herpesviruses like Epstein-Barr
virus (EBV) and human cytomegalovirus (HCMV) are the
most common [3, 6]. Intriguingly, most of the described
triggering viruses have a lytic replication cycle, which
incites a direct cytopathic effect on the infected cell, indu-
cing host tissue damage. Tissue damage in turn will result
in the release of multiple ‘alarmins’ or danger-associated
molecular patterns (DAMPs), molecules that were de-
scribed to contribute directly to disease pathogenesis in
HLH, in addition to eliciting immunopathology [7]. Thus,
two pathogenic processes may synergize in virus-associated
HLH: immune-mediated pathology and direct, virus-
mediated cytolytic effects.
Current pathophysiological insights into the role of vi-
ruses in HLH have mostly been derived from animal
models of primary HLH, in which mutant mouse strains
are inoculated with lymphocytic choriomeningitis virus
(LCMV) [8–11]. However, unlike the most abundant
viral triggers of HLH, this Arenavirus carries a (-)ssRNA
genome and is known to be noncytopathic in vivo [12].
Hence, LCMV will conceivably stimulate other pathogen
receptors and mediate different immune responses than
herpesviruses would, resulting in a course of infection
that may not fully reflect the underlying mechanisms of
most virus-induced HLH cases. Therefore, to more spe-
cifically study the pathogenic mechanisms exerted by
DNA viruses in secondary HLH, we recently developed a
new mouse model of herpesvirus-induced secondary
HLH, using mouse cytomegalovirus (MCMV) infection
in susceptible wild-type (WT) and IFN-γ-deficient
BALB/c mice [13]. Like EBV and HCMV, MCMV has a
lytic replication cycle, mediating direct cytopathic effects
in infected tissues and making this mouse model an in-
teresting tool to investigate the respective roles of un-
controlled viral replication and immunopathology in
HLH pathogenesis. In the current study, the contribu-
tion of lytic viral replication to disease development was
explored using different strategies. Organ titers of infec-
tious MCMV were correlated to the severity of key HLH
symptoms in the model. The possible pathogenic effects
of a sustained, non-cytolytic viral infection were imitated
using different methods. Firstly, the effect of ongoing,
non-specific immune receptor triggering was studied by
repeatedly administering CpG and/or polyinosinic-
polycytidylic acid (Poly(I:C)) as continuous Toll-like re-
ceptor (TLR) triggers. Secondly, to mimic MCMV-specific
immune cell triggering in a more precise way, UV-
inactivated, replication-deficient MCMV particles were re-
peatedly administered. Lastly, the lytic viral replication of
MCMV was inhibited in vivo using either polyclonal anti-
body neutralization or pharmacological inhibition by
antiviral cidofovir treatment. To decipher the role of im-
munopathology, a treatment with immunosuppressive
dexamethasone was tested in the MCMV-induced mouse
model.
Methods
Experimental design of the MCMV-induced secondary
HLH mouse model
IFN-γ-knockout (KO) mice on BALB/c background, cor-
responding WT BALB/c mice and WT C57BL/6 mice
were bred under specific pathogen-free conditions in the
Experimental Animal Centre of KU Leuven. Mice of 4-6
weeks old were age- and sex-matched within each experi-
ment. Experiments were carried out in a conventional ani-
mal facility in accordance with the recommendations of
the Animal Ethics Committee of KU Leuven. The protocol
was approved by the Animal Ethics Committee of KU
Leuven (P055/2012). Per mouse, an inoculum of 5 x 103
plaque-forming units (PFU) MCMV (Smith strain, VR-
1399, ATCC) in 100 μl PBS was injected intraperitoneally
(i.p.) on day 0. Stocks of MCMV were prepared from ho-
mogenates of salivary glands of NMRI mice after 2-3
weeks infection with a sublethal dose of MCMV, as a 10%
w/v solution in MEM medium. Only the clear supernatant
of salivary glands homogenates was used (600g, 10min, 4°
C) [14]. PBS-injected mice were included as controls.
Weight and rectal temperature of the mice was measured
daily. Mice were euthanized with Nembutal (Ceva) on day
2 post infection (p.i.), at the first signs of inflammation, or
on day 5 p.i., according to institutional ethical policies,
when chronic weight loss exceeded 20-25% of initial body
weight or when body temperature dropped below 34.5 °C.
The resulting murine HLH model, as described in refer-
ence [13] is illustrated in Fig. 1. Unless specified otherwise,
immunocompetent WT BALB/c mice were used in the
in vivo experiments.
Quantification of viral titers, polyclonal neutralization and
UV-inactivation of MCMV
The amount of infectious virus present in different organs
was determined by a plaque assay using a tenfold titration
of the supernatant of organ lysates on a monolayer of
C127I cells (CRL-1616, ATCC). Briefly, each organ sample
was thawed, weighed and lysed in 1 ml of MEM medium
with 2% heat-inactivated fetal bovine serum, 1% non-
essential amino acids, 1% sodium pyruvate, 1% penicillin/
streptomycin/glutamine and 1M HEPES. Only clear
supernatant was used (10 min, 600g, 4°C), debris was dis-
carded. Samples were serially diluted in a 96-well plate,
using 100 μl per well, in quintuplicate. Organ lysates were
incubated on the C127I monolayer for 2 hours (37°C, 5%
CO2). After removal of the lysates and addition of MEM
medium (components listed above), the cell cultures were
further incubated for 7 days, after which plaques were
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counted using light microscopy. Detection limit of the
assay was 2 PFU per organ. To inactivate the virus, two
approaches were used, UV-inactivation and neutralization
of MCMV using polyclonal antibodies. For UV inactiva-
tion, a stock solution of MCMV was incubated for 10 mi-
nutes under continuous agitation at a distance of 5 cm
underneath UV light (optimal conditions were established
in a pilot experiment, determining minimal exposure re-
quired for complete inactivation). Mice were injected i.p.
with 5 x 103 or 104 PFU of UV-inactivated MCMV at day
0, 2 and 4. Analysis was at day 5. UV-inactivated virus was
freshly prepared each time point and complete inactiva-
tion was confirmed via plaque assay. For MCMV
neutralization, polyclonal anti-MCMV antibodies (IgG,
neutralizing titer 64) were kindly provided by Prof. Dr. H.
J. Nauwynck (Ghent University). The isolation and titer
determination of these antibodies have previously been
described [15]. Diluted MCMV stock solution was incu-
bated for 1h at 37°C with a 1/32 dilution of neutralizing
antibodies, prior to infection of the mice on day 0. As an
isotype control, polyclonal IgG antibodies were purified
from serum of naïve BALB/c mice, and similarly incu-
bated with diluted MCMV stock solution.
Administration of CpG, Poly(I:C), cidofovir or
dexamethasone
CpG (50 or 100 μg per mouse, ODN1826, Integrated
DNA Technologies) and/or Poly(I:C) (50 or 200 μg per
mouse, Sigma-Aldrich) were administered i.p. to naive
mice on day 0, 2, 4, 6 and 8. Analysis was on day 9. A
single shot of cidofovir (50mg/kg body weight, kindly
provided by Gilead Sciences) was injected i.p. either at 2
hours or at 2 days p.i. with MCMV to limit viral
replication. A control group of naive mice was identi-
cally treated with cidofovir to rule out drug-specific ef-
fects. Dexamethasone 21-phosphate disodium salt (DEX,
Sigma-Aldrich) was injected i.p., daily, starting on day 2
p.i. with MCMV, in a dose-response set-up, comparing
1, 2, 4, 8 and 16 mg/kg body weight. As these different
concentrations did not result in clinical or laboratory
differences, the data were combined in one DEX-treated
experimental group. All molecules were diluted to the
required concentration in sterile PBS. Control MCMV-
infected mice were injected daily with an equal volume
of PBS. All experiments were performed using a ran-
domized design to avoid cage effects.
Blood analysis and quantification of liver enzymes
Blood samples were obtained via cardiac puncture with
heparin (LEO Pharma). Blood cell analysis was performed
with a Cell-Dyn 3700 Hematology Analyzer (Abbott Diag-
nostics). Plasma concentrations of alanine transaminase
(ALT) were measured spectrophotometrically using a UV-
kinetic method according to the manufacturer’s instruc-
tions (ALT (SGPT) Reagent Set, Teco Diagnostics).
Quantification of soluble CD25 (sCD25) and ferritin using
ELISA
The protein level of sCD25 was determined in plasma
according to the manufacturers’ instructions (DuoSet,
R&D Systems). The lower ELISA detection limit was 78
pg/ml. A sandwich ELISA detecting the ferritin heavy
chain was kindly offered by Dr. Paolo Santambrogio
(San Raffaele Scientific Institute, Il Dipartimento di Bio-
tecnologie, Milan, Italy) [16]. The lower ELISA detection
limit was 9.76 ng/ml.
Fig. 1 Schematic representation of the murine model of virus-associated secondary HLH. HLH-like disease is present in WT and IFN-γ-KO BALB/c
mice, not in WT C57BL/6 mice. Mice are infected i.p. with 5 x 103 PFU of MCMV and analyzed 5 days post infection. * = fever, pancytopenia,
hemophagocytosis, hyperferritinemia and elevated soluble CD25 levels; ** = lymphadenopathy, liver dysfunction and decreased NK cell numbers;
*** = in addition to WT BALB/c mice also splenomegaly, coagulopathy and decreased NK cell cytotoxicity. ↑ = more pronounced as compared to
infected WT BALB/c mice; NK = natural killer; KO = knockout; MCMV = mouse cytomegalovirus; PFU = plaque-forming units; WT = wild-type
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Single-cell suspensions, cytospins and flow cytometry
For single-cell suspensions, white blood cells were
obtained from blood after lysis of red blood cells with
NH4Cl. Lung white blood cells were obtained from
density gradient centrifuged lung cell suspensions
(Percoll 40% and 72%, GE Healthcare). Lymph node cells
were extracted from both inguinal lymph nodes. For
cytospin preparations, single-cell suspensions were spun
on a glass slide and stained with H&E. For flow cytome-
try, cell suspensions were incubated with anti-CD16/
anti-CD32 (Miltenyi Biotec) and stained with the follow-
ing monoclonal antibodies: CD3e (clone 145-2C11),
CD8a (53-6.7), CD25 (PC61.5), CD49b (DX5), CD69
(H1.2F3), CD122 (5H4) (eBioscience, BD Biosciences or
BioLegend). Dead cells were excluded using propidium
iodide (PI) or Zombie Aqua Fixable Viability Dye (BioLe-
gend). Samples were run with a FACSCalibur using
CELLQuest software or an LSR Fortessa X-20 using
FACSDiva software (all BD Biosciences). Live singlet
cells (PI- or ZombieAqua-) were analyzed with FlowJo
(Version 10).
Statistical analysis
Data with two experimental groups were analyzed via a
two-tailed nonparametric Mann-Whitney U test. For
comparison of three or more groups, a nonparametric
Kruskal-Wallis test was performed, followed by Dunn’s
multiple comparison post-test. For correlation analyses,
a two-tailed nonparametric Spearman test was applied.
Outliers were identified using a Grubbs’ test and all de-
viated more than 3 times the standard deviation from
the group median. GraphPad Prism 5.00 was utilized.
Results
Infectious viral titers are higher in MCMV-susceptible
mice, but do not correlate with severity of HLH-like
symptoms
C57BL/6 mice and BALB/c mice are known to be respect-
ively resistant and susceptible to mouse cytomegalovirus
(MCMV) infection [17, 18]. When wild-type (WT)
C57BL/6, WT BALB/c and IFN-γ-KO BALB/c mice were
infected with MCMV, the infectious viral titer in these
strains differed significantly from day 2 up to day 5 post
infection (Fig. 2a, b). The viral load was generally higher
in IFN-γ-KO mice than in corresponding WT BALB/c
mice, while WT C57BL/6 mice displayed lower to un-
detectable viral titers as they managed to rapidly control
the virus. As infected IFN-γ-KO mice show a more
complete HLH spectrum when compared to infected WT
BALB/c mice, and as infected WT C57BL/6 mice display
little to no HLH-like symptoms [13], this raised the ques-
tion whether inordinate replication of MCMV, a cytolytic
virus, could be the main cause of the observed HLH-like
syndrome.
To assess a possible relationship between the develop-
ment of the HLH-like syndrome and the rate of viral
replication, with its concomitant cytolytic effects, a cor-
relation analysis was performed between the viral load in
WT BALB/c mice and the severity of different HLH
symptoms. Day 5 post infection was chosen for this ana-
lysis since the highest viral titers were observed at this
time point (Fig. 2a, b). The spleen viral titer was selected
since, at this time point in the model, MCMV is pre-
dominantly present in the spleen, compared to lung,
liver and kidneys (Fig. 2c). Of note, an even higher viral
load was often detected in salivary glands, in line with
reports identifying the acinar glandular epithelial cells as
the main site of ongoing productive infection. However,
since the virus may persist for weeks in the glands even
when viremia has been successfully cleared and MCMV
is no longer detectable in any visceral organs, salivary
gland titers do not reflect the systemic disease course as
accurately as spleen viral titers do [18–21]. Key symp-
toms developing in MCMV-infected BALB/c mice were
previously described [13] and include severe weight loss,
fever on day 2 post infection, hypothermia on day 5 post
infection, pancytopenia, hemophagocytosis in different or-
gans and in peripheral blood, hyperferritinemia, elevated
plasma levels of soluble CD25 (sCD25), a decreased per-
centage of natural killer (NK) cells in different organs and
in peripheral blood, increased plasma levels of liver en-
zymes (alanine transaminase, ALT), and enlarged lymph
nodes. A Spearman correlation test was performed on 8
independent experiments, with 15 to 25 infected mice in
each experiment. In none of these experiments could a
significant relationship be detected between spleen viral ti-
ters of MCMV and the extent of body weight loss post in-
fection, fever, lymphopenia, thrombocytopenia, anemia,
hyperferritinemia, plasma levels of sCD25, remaining per-
centage of NK cells in lung, plasma levels of ALT, or the
extent of lymphadenopathy (Fig. 2d-m). As some outliers
were present in the dataset, depicted as triangles in Fig. 2,
the correlation analyses were additionally ran in the ab-
sence of outliers, however once more, no significant corre-
lations were detected. Thus, although the infectious viral
titer is the highest in mouse strains developing an HLH-
like syndrome post MCMV infection, the titers do not
correlate with the severity of key HLH features.
Persistent stimulation of TLR3, in contrast to TLR9, is not
sufficient to induce an HLH-like syndrome in WT BALB/c
mice
Since the statistical correlations did not provide conclusive
evidence for a link between the extent of viral replication
and the severity of the HLH-like symptoms in the mouse
model, we investigated whether lytic viral replication was
an essential requirement to elicit HLH disease or whether
non-cytolytic immunostimulation would suffice to induce
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HLH pathology. MCMV is a dsDNA virus that predomin-
antly triggers TLR9 [22], and therefore persistent CpG-
mediated stimulation of TLR9 would be a valid way to
mimic MCMV-mediated immune cell triggering. In fact,
this strategy has been reported in C57BL/6 mice as a
mouse model of secondary HLH or macrophage activation
syndrome [23]. In addition to TLR9, TLR3 plays a signifi-
cant, though less crucial role in the immune response
against MCMV by recognizing dsRNA that is presumably
formed during bidirectional transcription of the MCMV
genome [22]. We therefore examined the effects of repeti-
tive TLR9, TLR3 or combined TLR3 and -9 triggering on
the induction of HLH-like pathology, in a dose-response
set-up. As previously reported in C57BL/6 mice [23], re-
petitive CpG stimulation of BALB/c mice resulted in a
mild HLH syndrome (Fig. 3). Weight loss occurred, but
the mice recovered without fatalities (Fig. 3a). No hyper- or
hypothermia was observed (Fig. 3b). The mice did develop
hepatosplenomegaly, and lymphadenopathy only following
the highest dosage of CpG (Fig. 3c). Hematologically, CpG-
Fig. 2 Spleen viral titers are not correlated with the severity of HLH-like symptoms. a Comparison of spleen viral titer (PFU/g) in different mouse
strains on day 2 post infection (p.i.) and b day 5 p.i.. c Titer of infectious virus in spleen, lung, liver and kidney (PFU per g organ tissue) of WT
BALB/c mice on day 5 p.i.. d-m Correlation analysis between the infectious viral titer in spleen (PFU/g) on day 5 p.i. and d percentage change in
body weight relative to body weight at day 0 p.i., e rectal body temperature (°C) on day 2 p.i., f-h absolute lymphocyte, platelet and red blood
cell (RBC) count in whole blood, plasma concentration of i ferritin heavy chain (ng/ml) and j sCD25 (pg/ml), k percentage of NK cells in lungs,
gated as CD122+CD49b+CD3-ZombieAqua- cells, l plasma concentration of ALT (IU/L) and m total cell number of inguinal lymph nodes. a-m Dots
represent individual animals. Outliers are depicted with a triangle▲. Horizontal bars refer to median group values. d, f-m Data obtained on day 5 p.i..
a-c Depicted data are from 1-3 experiments and representative of >5 or d-m 8 independent experiments with >5 mice per experimental group. d, f-j,
l-m Data from 1 experiment with 25 BALB/c MCMV mice. e, k Data from 1 experiment with 20 and 15 BALB/c MCMV mice, respectively. a-m Detection
limit of the plaque assay is 2 PFU/organ, represented by grey boxes or a dotted line. i, j Lower ELISA detection limits are indicated with a dotted line.
ALT = alanine transaminase, KO = knockout, LN = lymph node, NK = natural killer, PFU = plaque-forming units, r = Spearman correlation coefficient,
sCD25 = soluble CD25, temp. = temperature, WT = wild-type. p > 0.05; ** p < 0.01; *** p < 0.001; Kruskal-Wallis with Dunn’s post-test for multiple
comparisons, Spearman test for correlation analysis
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stimulated mice developed thrombocytopenia and anemia,
though no lymphopenia (Fig. 3d). Plasma ferritin levels
were elevated (Fig. 3e), but remained an order of magnitude
lower than the levels measured in the MCMV-induced sec-
ondary HLH mouse model [13]. Splenic NK cells decreased
significantly (Fig. 3f), while liver enzymes were not in-
creased following chronic TLR9 activation (Fig. 3g). In con-
trast, repetitive stimulation of TLR3, using the TLR3
agonist Poly(I:C), was not able to elicit pronounced HLH-
like symptoms in WT BALB/c mice. Almost no weight loss
Fig. 3 Repeated CpG, but not Poly(I:C) injections induce a mild HLH-like syndrome in WT BALB/c mice. a Percentage change in body weight relative
to initial body weight at day 0. Median with interquartile range of 5 mice per experimental group. b Rectal body temperature (°C). Dotted line = 38.5°C
(fever) or 34.5°C (endpoint as an indication of mortality). Median with interquartile range of 5 mice per experimental group. c Absolute spleen, liver
and lymph node (LN) weight (g). Two inguinal LN were measured. d Absolute lymphocyte, platelet and red blood cell (RBC) count in whole blood. e
Plasma concentration of the ferritin heavy chain (ng/ml). f Percentage of NK cells in spleen, analyzed as CD49b+CD122+ of CD3-PI- splenocytes. g
Plasma concentration of ALT (IU/L). c, d, f, g Dots represent individual animals. e Dots represent the average of two dilutions for one single mouse.
Horizontal bars refer to median group values. c-g Data were obtained on day 9 post injection. ALT = alanine transaminase, CpG = 50μg or 100μg per
mouse every other day, NI = not injected, PI = propidium iodide, PolyIC = 50μg or 200μg per mouse every other day, temp. = temperature, WT =
wild-type. * p < 0.05; ** p < 0.01; *** p < 0.001; Mann-Whitney U test. Depicted data are from 1 experiment, representative of 2 experiments with 5
mice per experimental group
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was observed (Fig. 3a) and the mice did not develop fever
or hypothermia (Fig. 3b). Hepatosplenomegaly, lymphaden-
opathy, lymphopenia and anemia were absent (Fig. 3c, d),
only thrombocytopenia occurred at the highest concentra-
tion of Poly(I:C) (Fig. 3d). Spleen NK cells were not de-
creased (Fig. 3f), but the highest dose of Poly(I:C) did elicit
a slight increase in the plasma levels of ferritin and ALT,
though not statistically significant (Fig. 3e, g). Thus, in con-
trast to repeated stimulation of TLR9, persistent triggering
of TLR3 was not sufficient to induce HLH pathology in
WT BALB/c mice. Lastly, the combined stimulation of
TLR3 and TLR9 did not result in any additive pathological
effects. The combinatory activation of both TLRs mostly
mirrored the effects of TLR9 agonism alone, indicating that
in contrast to TLR9, TLR3 activation is of minor import-
ance in murine secondary HLH pathogenesis.
Antibody-neutralized or UV-inactivated MCMV is no lon-
ger able to induce an HLH-like syndrome in WT BALB/c
mice
Since a viral infection activates the host immune system
in multiple intricate ways, solely TLR triggering is most
likely insufficient to recapitulate the full response of the
host to persistent MCMV infection. To establish
whether challenges with viral particles in the absence of
lytic viral replication would be sufficient to induce HLH
disease, two different methodologies were used. In a first
approach, MCMV was neutralized in vitro with MCMV-
specific polyclonal antibodies [15], prior to infection of
the mice. As an isotype control, MCMV treated with a
cocktail of irrelevant polyclonal IgG antibodies was used.
In contrast to isotype-treated MCMV, neutralized
MCMV was no longer capable to induce full-blown
HLH disease (Fig. 4). No weight loss, fever, lymphopenia,
anemia, or hyperferritinemia developed (Fig. 4a-c, e, f ).
Only thrombocytopenia was observed (Fig. 4d). Interest-
ingly, the neutralization was less efficient in 2 mice, that
still displayed infectious virus in the spleen on day 5 post
infection (Fig. 4g). These mice, indicated as open dots in
Fig. 4, developed more pronounced HLH-like features
than did their completely neutralized counterparts, cor-
roborating a role for productive viral replication in the
onset of murine virus-associated secondary HLH.
In the second approach, a sustained, non-replicating
MCMV infection was mimicked by inactivating the virus
through UV light exposure. The non-infectious viral parti-
cles were repeatedly administered to WT BALB/c mice to
reproduce persistent MCMV-antigenic immunostimula-
tion. UV-inactivated MCMV produces no direct lytic ef-
fects as it cannot replicate nor induce viral gene expression,
but can still trigger pathogen receptors [24–26], allowing
the study of MCMV-related immunostimulation without
any confounding cytolytic effects. Repeated administration
of inactivated virions did not induce clinical HLH disease
in the mice. No weight loss (Fig 5a), pronounced fever
(Fig. 5b, left panel), or hypothermia (Fig. 5b, right panel)
developed. Additionally, ferritin plasma levels were not el-
evated (Fig. 5c). In conclusion, abortive infection with ei-
ther antibody-neutralized or UV-inactivated MCMV was
not sufficient to initiate HLH pathogenesis in WT BALB/
c mice.
Restriction of viral replication by cidofovir rescues MCMV-
infected IFN-γ-KO mice from a lethal HLH-like syndrome
To further investigate whether lytic viral replication was
necessary to induce and drive progression of fulminant
HLH disease, MCMV was administered to IFN-γ-KO
mice together with a potent inhibitor of viral replication,
the acyclic nucleoside phosphonate cidofovir. IFN-γ-KO
mice were chosen in this setup since they display higher
viral titers than WT BALB/c mice, presumably allowing
for a more pronounced effect of the antiviral treatment.
Cidofovir serves as an alternative substrate for the viral
DNA polymerase, which upon incorporation into the
viral DNA strand, obstructs further elongation [27]. In
this way, cidofovir inhibits viral DNA synthesis but does
not affect viral cell entry and expression of immunogenic
immediate early and early antigens [28]. Thus, cidofovir
prevents cellular damage due to lytic replication, but allows
stimulation of extracellular and intracellular pathogen re-
ceptors by viral proteins. Cidofovir was administered at two
different time points, to monitor the effects of MCMV on
the initiation and further propagation of the HLH-like dis-
ease. Administration of cidofovir on day 0 p.i. efficiently
inhibited viral replication, as no infectious virus could be
detected in spleen tissue on day 5 p.i. (Fig. 6a, left panel).
This prevented the development of the MCMV-induced
HLH-like syndrome. Treated mice did not display weight
loss or hypothermia, indicating 100% survival, whereas un-
treated infected IFN-γ-KO mice required euthanasia by day
5 p.i. according to institutional ethical policies. Key symp-
toms such as fever, lymphopenia, anemia, hemophagocyto-
sis, lymphadenopathy, hyperferritinemia, elevated plasma
levels of liver enzymes and decreased NK cell numbers
were absent after cidofovir treatment (data not shown).
Only splenomegaly and thrombocytopenia did develop in
MCMV-infected IFN-γ-KO mice treated with cidofovir on
day 0 (data not shown), suggesting that these symptoms
may not be linked to viral replication but are rather conse-
quent to the immune response elicited against immediate
early and/or early MCMV antigens.
The potent effect of cidofovir on day 0 led us to inves-
tigate its therapeutic potential in limiting the further
progression of HLH disease in the mouse model. As no
drug-related effects of cidofovir were observed in naive
IFN-γ-KO mice in the previous experiment, the treat-
ment was considered safe and this experimental group
was not included in the following experiments. Cidofovir
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was administered to MCMV-infected IFN-γ-KO mice on
day 2 p.i., when first disease symptoms appeared. The
treatment resulted in strongly reduced (20- to 70-fold)
but detectable viral titers in spleen on day 5 p.i. (Fig. 6a,
right panel). Weight loss quickly reversed after cidofovir
treatment (Fig. 6b) and all cidofovir-treated mice sur-
vived the infection. The development of fever was un-
altered as the treatment was only started after its onset
(Fig. 6c). Many HLH-like symptoms were resolved or at-
tenuated. Levels of ferritin, ALT, and the number of NK
cells in blood were normalized (Fig. 6i, k, l), while lym-
phopenia, thrombocytopenia and hemophagocytosis
were attenuated after cidofovir treatment (Fig. 6e, f, h).
Nevertheless, splenomegaly, anemia and elevated plasma
levels of sCD25 were present to a similar extent with or
without therapeutic cidofovir treatment (Fig. 6d, g, j), in-
dicating that these symptoms are less related to viral
replication but probably represent the effects of immu-
nopathologic mechanisms.
In conclusion, inhibition of lytic viral replication was
able to prevent and cure the MCMV-induced HLH-like
disease in IFN-γ-deficient mice, suggesting that both the
initiation and propagation of full-blown HLH in this
mouse model is dependent on viral replication and
Fig. 4 Neutralization of MCMV with polyclonal antibodies inhibits development of fulminant HLH in WT BALB/c mice. a Percentage change in
body weight relative to initial body weight at day 0 post infection (p.i.). Median with interquartile range of 3-5 mice per experimental group. b
Rectal body temperature (°C) on day 2 p.i. Dotted line = 38.5°C (fever). c-e Absolute lymphocyte, platelet and red blood cell (RBC) count in whole
blood. f Plasma concentration of the ferritin heavy chain (ng/ml). Dots represent the average of two dilutions for one single mouse. Dotted line
represent the lower ELISA detection limit. g Titer of infectious virus in spleen (PFU per g spleen tissue). b-g Data were obtained on day 5 p.i.. Dots
represent individual animals. / = MCMV without prior incubation, IgG = MCMV incubated 1h with isotype control antibodies, Neutra = MCMV
incubated 1h with anti-MCMV neutralizing antibodies as described in M&M, NI = not infected, RBC = red blood cells, temp. = temperature. ○ =
open dots in the ‘Neutra’ group indicate mice in which neutralization was not completely efficient. * p < 0.05; ** p < 0.01; Kruskal-Wallis with
Dunn’s post-test for multiple comparisons. Depicted data are from one experiment
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sustained viremia, even though a limited set of symp-
toms appears to be driven by immunopathology.
Immunosuppressive dexamethasone treatment
attenuates limited HLH symptoms in MCMV-infected WT
BALB/c mice
The experiments with cidofovir suggested that at least
part of the HLH-like syndrome was less dependent on
viral replication but rather resulted from the concomi-
tant immune response. CD8+ T cells and CD11b+ cells
are highly activated post MCMV infection, as previously
described [13], and the excessive immune activation may
play a role in mediating immunopathology. To investi-
gate this, an immunosuppressive drug was administered
daily to MCMV-infected BALB/c mice starting day 2
post infection. Dexamethasone (DEX) was chosen as it is
the preferred steroid treatment in the HLH-2004 thera-
peutic protocol [29].
Weight loss post infection was not counteracted by
DEX treatment (Fig. 7a) and the development of fever was
unaltered since immunosuppression was only started after
the onset of this symptom (Fig. 7b). Lymphopenia was still
present, although the lymphocytes in some DEX-treated
mice returned to normal levels (Fig. 7d). The drop in
platelet numbers following MCMV infection was signifi-
cantly attenuated in the animals receiving DEX (Fig. 7e).
Hemophagocytosis, hyperferritinemia and increased
levels of plasma liver enzymes were present to a simi-
lar extent in PBS-treated and DEX-treated MCMV-
infected mice (Fig. 7g, h, k). Steroid treatment re-
duced the number of NK cells post infection even
further (Fig. 7j). The most pronounced therapeutic ef-
fects of the immunosuppressive treatment were ob-
served in the correction of anemia (Fig. 7f ) and in
the normalization of the plasma concentration of
sCD25 (Fig. 7i), a measure for the degree of T cell ac-
tivation in HLH. In line with the sCD25 data, the
total number of activated CD8+ T cells in lymph
nodes decreased following DEX treatment, although
the relative percentage of activated cells in the CD8+
T cell population remained equal or even slightly in-
creased (Fig. 7l, m). Notwithstanding the adequate sup-
pression of T cell activation, the immunosuppressive
treatment did not significantly hamper control over the
viral infection, as demonstrated by similar splenic viral ti-
ters in the presence or absence of DEX (Fig. 7c).
In conclusion, immunosuppression using DEX was in-
sufficient to temper the HLH-like syndrome in MCMV-
infected WT BALB/c mice, although a limited number of
parameters, i.e. the degree of anemia, thrombocytopenia
and elevation of sCD25 levels, appeared to be immune-
mediated.
Fig. 5 Infection of WT BALB/c mice with UV-inactivated MCMV does not elicit an HLH-like syndrome. UV = 5 x 103 PFU of UV-inactivated MCMV,
UV x 2 = 104 PFU of UV-inactivated MCMV, administered every other day. a Percentage change in body weight relative to initial body weight at
day 0 post infection (p.i.). Median with interquartile range of 5 mice per experimental group. b Rectal body temperature (°C) on day 2 (left panel)
and on day 5 p.i. (right panel). Dotted line = 38.5°C (fever) or 34.5°C (endpoint as an indication of mortality). Dots represent individual animals. c
Plasma concentration of the ferritin heavy chain (ng/ml) on day 5 p.i.. Dots represent the average of two dilutions for one single mouse. Dotted
line represents the lower ELISA detection limit. b-c Horizontal bars refer to median group values. NI = not infected, PFU = plaque-forming units,
temp. = temperature. * p < 0.05; ** p < 0.01; Kruskal-Wallis with Dunn’s post-test. Depicted data are from one experiment.
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Discussion
Hemophagocytic lymphohistiocytosis is a hyperinflam-
matory disorder provoking high morbidity and risk of
mortality in both children and adults. In recent cohorts,
overall fatality has been estimated at 30%, but may vary
considerably between different HLH subtypes [30]. In
particular, HLH associated with active EBV disease is
known for its aggressive disease course and poor prog-
nosis [31]. As of yet, no specific treatments exist for
virus-associated secondary HLH, and emphasis is placed
on the rapid elimination of the triggering infection
through antiviral therapy, combined with the standard
immunosuppressive treatment [29]. To improve the out-
come of virus-associated HLH and to devise more tar-
geted therapies for this HLH subtype, its pathogenesis
needs to be elucidated into further detail. In this manu-
script, a recently described MCMV-induced mouse
model of herpesvirus-associated secondary HLH was uti-
lized to gain further insights into the role of viruses and
the antiviral immune response in the development of
Fig. 6 Antiviral cidofovir treatment rescues MCMV-infected IFN-γ-KO BALB/c mice from severe HLH-like disease. a Titer of infectious virus in spleen
(PFU per g spleen tissue) with/without cidofovir (CDV) treatment on day 0 (d0) (left panel) or day 2 (d2) (right panel) post infection (p.i.). Plaque assay
detection limit 2 PFU/organ, indicated by dotted line. b Percentage change in body weight relative to body weight at day 0 p.i.. Median with inter-
quartile range of 5 mice per experimental group. Weight change was significantly different between infected CDV-treated and infected non-treated
mice, on day 4 and 5 p.i. (**). Arrow indicates time point of CDV treatment. c Rectal body temperature (°C) on day 2 p.i.. Dotted line = 38.5°C (fever). d
Absolute spleen weight (g). e-g Absolute lymphocyte, platelet and red blood cell (RBC) count in whole blood. h Percentage of hemophagocytes
detected in cytospins of blood-derived WBC. i Plasma concentration of the ferritin heavy chain (ng/ml). j Plasma concentration of sCD25 (pg/ml). k
Percentage of NK cells in whole blood, gated as CD122+CD49b+ cells of CD3-PI- cells. l Plasma concentration of ALT (IU/L). a, c-g, j-l Dots represent
individual animals. h Dots represent the average of triplicate counts of 100 cells from one individual mouse. i Dots represent the average of two
dilutions for one single mouse. Horizontal bars refer to median group values. i, j Dotted lines represent the lower ELISA detection limit. a, d-l Data
were obtained on day 5 p.i.. ALT = alanine transaminase, CDV = cidofovir 50mg/kg injected day 0 (d0) or day 2 (d2) p.i., NI = not infected, NT = not
treated with CDV, PI = propidium iodide, temp. = temperature, WBC = white blood cells. * p < 0.05; ** p < 0.01; Mann-Whitney U test for single
comparison, Kruskal-Wallis with Dunn’s post-test for multiple comparisons. Depicted data are from 1 experiment and representative of 2
independent experiments
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Fig. 7 (See legend on next page.)
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HLH. Previous findings in this model had indicated that
mice lacking the pro-inflammatory cytokine IFN-γ dis-
played a more severe spectrum of HLH, in comparison
to their WT counterparts [13], suggestive of a protective
role for the cytokine. These observations were highly
relevant as they reflected the occurrence of IFN-γ-
independent HLH-like disease in a number of interesting
case reports (reviewed in references [32] and [33]), but
were in clear contrast with data from primary HLH
models, in which IFN-γ was designated as the key patho-
genic cytokine since its depletion resulted in complete in-
hibition of the fatal HLH-like syndrome [8, 34]. The lack
of antiviral IFN-γ activity and the correspondingly high
viral titers detected in infected IFN-γ-deficient mice, led
us to speculate a role for uncontrolled MCMV replication
in the worsening of HLH-like disease. However, when WT
mice were inoculated with doses of MCMV that were 2, 5,
or even 25 times higher, mimicking unrestrained viral pro-
liferation in the absence of IFN-γ, a similar disease
spectrum as observed in IFN-γ-KO mice could not be in-
duced [13]. Hence, other, non-virus-mediated mechanisms
must play a role in disease development. The present art-
icle investigated into closer detail the respective contribu-
tions of virus-mediated pathology and immunopathology
in the development of secondary HLH.
Comparison of splenic viral titers in WT C57BL/6,
WT BALB/c and IFN-γ-KO mice post infection with
MCMV revealed a trend of increasing viral load in the
mouse strains that developed HLH. Resistant C57BL/6
mice managed to clear the virus and displayed low to
undetectable titers of MCMV, while IFN-γ-KO mice,
who develop the most complete spectrum of HLH, pre-
sented with the highest viral titers, consistent with the
hypothesis that the severity of the HLH-like syndrome
in the mutant mice was directly linked to increased lytic
viral replication. Nonetheless, the splenic viral titer of in-
fected WT and IFN-γ-KO BALB/c mice differed on aver-
age only 5-fold, while both strains displayed very
different HLH symptoms [13], indicating that increased
disease severity may not be exclusively attributed to-
augmented viral proliferation but may emanate from
additional differences in immune activation and immu-
nopathology. Indeed, correlation analysis of the splenic
viral titer in infected mice with key HLH symptoms such
as fever, cytopenia, hyperferritinemia, etc. supported no
direct relationship between the extent of viral replication
and the severity of murine HLH. On the other hand, re-
peated immunostimulation with UV-inactivated MCMV
particles did not induce any HLH-like symptoms in WT
BALB/c mice, indicating that the HLH syndrome is -at
least for its induction- dependent on a replication-
competent viral agent. Neutralization of MCMV with
polyclonal antibodies confirmed these findings, as the
development of full-blown HLH was completely abol-
ished in neutralized MCMV-injected mice. Similar re-
sults were obtained when the replication of MCMV was
halted in vivo, by administering the potent antiviral
agent cidofovir at the time point of infection. In the ab-
sence of viral replication, the general HLH syndrome
was not observed, although individual features like
splenomegaly and thrombocytopenia did develop. Cido-
fovir treatment was also used to halt viral replication
in vivo at a later time point of the infection, in order to
investigate whether ongoing viral replication and sus-
tained viremia were necessary to propagate HLH. The
antiviral treatment attenuated the HLH-like syndrome,
reversing weight loss and rescuing all infected mice.
Analogous to the earlier cidofovir treatment, some
HLH-like symptoms were not reduced by late treat-
ment with cidofovir, i.e. splenomegaly, anemia and ele-
vated sCD25 were still present, while lymphopenia,
thrombocytopenia and hemophagocytosis were attenu-
ated but not absent. Disease initiation and progression
to full-blown HLH is thus dependent on viral replica-
tion, although a limited number of symptoms may be
mediated by the immune response against viral pro-
teins, such as the immediate early and early MCMV
antigens.
(See figure on previous page.)
Fig. 7 Daily dexamethasone treatment does not alleviate the HLH-like syndrome in MCMV-infected WT BALB/c mice. DEX = dexamethasone,
range 1-16 mg/kg per day, starting from day 2 post infection (p.i.), indicated by color codes from blue to red for the lowest to highest dose. a
Percentage change in body weight relative to initial body weight at day 0 p.i.. Median with interquartile range of 9-10 mice per experimental
group. b Rectal body temperature (°C) on day 2 p.i.. Dotted line = 38.5°C (fever). c Titer of infectious virus in spleen (PFU per g spleen tissue).
Plaque assay detection limit 2 PFU/organ. d-f Absolute lymphocyte, platelet and red blood cell (RBC) count in whole blood. g Percentage of
hemophagocytes detected in cytospins of blood-derived WBC. h Plasma concentration of the ferritin heavy chain (ng/ml). i Plasma concentration of
sCD25 (pg/ml). j Percentage of NK cells in lymph nodes (LN), gated as CD122+ CD49b+ cells of CD3- ZombieAqua- cells. Cells from both inguinal LN. k
Plasma concentration of ALT (IU/L). l, m Percentage (left panel) and absolute number (right panel) of activated cytotoxic T cells from both inguinal
lymph nodes, gated as CD69+ or CD25+ cells of CD8+ ZombieAqua- cells. b-f, i-m Dots represent individual animals. g Dots represent the average of
triplicate counts of 100 cells from one individual mouse. h Dots represent the average of two dilutions for one single mouse. Horizontal bars refer to
median group values. h, i Dotted lines represent the lower ELISA detection limit. c-m Data were obtained on day 5 p.i.. ALT = alanine transaminase, NI
= not injected, PFU = plaque-forming units, sCD25 = soluble CD25, temp. = temperature, WBC = white blood cells, WT = wild-type. * p < 0.05; ** p <
0.01; *** p < 0.001; Mann-Whitney U test for single comparison, Kruskal-Wallis with Dunn’s post-test for multiple comparisons. Depicted data are from
two independent experiments
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Neutralization of MCMV with polyclonal antibodies
not only allowed to focus on the role of viral infection in
the HLH mouse model, but also permitted to exclude a
pathogenic role for any other contaminating compo-
nents in the MCMV stock solution, derived from salivary
gland (SG) homogenates. In literature, there has been
some debate regarding the use of SG-derived viral prep-
arations, as they contain a crude mixture of not only
viral particles but also cytokines, chemokines, TLR
ligands, hormones, and other cellular proteins. As these
components originate from inflamed, immunologically
active tissue [20, 35], they could contribute to the
inflammatory reaction following infection with SG-
MCMV. In vivo infection with SG-MCMV is known to
be more aggressive than cell culture-passaged MCMV.
The difference in virulence can on the one hand be ex-
plained by the presence of immuno-active components
in SG homogenates, but may on the other hand be
related to a partial loss in host affinity or change in
organ or cellular tropism following serial passages in
vitro [18, 21, 36–38]. Tissue-derived components in
SG-MCMV may increase the inflammatory reaction to
viral inoculation and could speed up the development of
immunopathology, as such being co-responsible for pro-
voking HLH in the murine model. Nonetheless, injection
with neutralized SG-MCMV pointed out that the non-
viral immuno-inflammatory components present in SG
homogenates were not able to elicit HLH-like disease by
themselves, indicating that the uncontrolled viral infec-
tion was indeed the key driver of full-blown HLH devel-
opment. Synergistic activities between the virus and
non-viral components can however not be excluded
from these experiments.
Uncontrolled pathogen replication has been empha-
sized as a pathogenic factor in other animal models of
infection-associated secondary HLH. In an EBV-induced
humanized mouse model, mice displayed persistently
high viremia and disease severity correlated with EBV
DNA production. Plasma EBV titers also correlated with
the level of T cell hyperactivation and IFN-γ hypersecre-
tion, linking the magnitude of the productive infection
to the development of immunopathology. Additionally,
inoculation of the humanized mice with heat-inactivated
EBV did not induce any HLH symptoms [39], similar to
our results with UV-inactivated MCMV. Likewise, in a
Salmonella-induced mouse model of bacteria-associated
HLH, disease severity was correlated with high splenic
and hepatic bacterial loads. Only the most severely in-
fected mice fulfilled six of the eight HLH-2004 diagnos-
tic criteria. The bacterial load could statistically be
linked to the severity of individual HLH symptoms such
as cytopenia, hepatosplenomegaly and hyperferritinemia
[40]. In the MCMV-induced mouse model, however, we
could not confirm a direct statistical relationship.
Models of primary HLH are equally reliant on sus-
tained viremia and ongoing viral replication to induce
the HLH syndrome [8, 9]. Due to the inherent defect in
granule-mediated cytotoxicity, the viral trigger, in most
cases lymphocytic choriomeningitis virus (LCMV), can-
not be cleared and proliferation is unrestrained. None-
theless, the extent of viral replication does not seem to
correlate fully with disease severity. In LCMV-infected
syntaxin11-deficient mice, the HLH syndrome pro-
gressed from severe, acute disease to a chronic and mod-
erate syndrome, irrespective of the viral titer [10].
Furthermore, cytokine hyperproduction and CD8+ T cell
activation in LCMV-infected perforin- and Lyst-deficient
mice were independent of the splenic viral load [41].
Antibodies against LCMV, neutralizing the serum viral
titer in perforin-deficient mice, were shown to mitigate
the disease, allowing for prolonged survival in a part of
the mice, but not full recovery. On the other hand,
chronic administration of a synthetic LCMV peptide,
simulating persistent antigen stimulation, only partially
replicated the HLH syndrome in perforin-deficient mice,
in a milder degree as well [8]. Together, these data indi-
cate a partial dependence of the primary HLH model on
unrestricted LCMV replication.
In line with the findings in primary and secondary
HLH mouse models, reports of patients with virus-
associated HLH corroborate the involvement of sus-
tained viremia in the severity and outcome of the syn-
drome. In adult secondary HLH, the presence of a viral
infection constituted a prognostic factor for poor out-
come [42]. In EBV-associated HLH, EBV genome copy
numbers were correlated with disease outcome. Patients
who achieved remission managed to control the virus
after treatment initiation, while patients who did not re-
spond to therapy continued to present with high EBV
copy numbers in serum [43]. The viral load may also be
used to distinguish EBV-associated HLH from the less
severe EBV-induced infectious mononucleosis. Viral ti-
ters in patients with EBV-associated HLH can be up to
104 times higher when compared to patients with infec-
tious mononucleosis [43, 44]. In addition, the percentage
of EBV-infected peripheral blood mononuclear cells is
on average 10 times higher in EBV-HLH, compared to
infectious mononucleosis [45].
To further dissect the contributions of virus- versus
immune-mediated pathology in the pathogenesis of
MCMV-induced murine HLH, we investigated whether
immunopathology mediated by excessive triggering of
pathogen receptors played a role. Virus-mediated immu-
nostimulation was mimicked by administering TLR li-
gands to the mice. Repeated administration of Poly(I:C),
a TLR3 ligand, did not induce any HLH-like symptoms,
while repetitive injections of CpG, a TLR9 agonist, did.
These results are in line with observations made by
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Behrens et al. [23], who reported a failure to induce
HLH-like disease in C57BL/6 mice repeatedly injected
with Poly(I:C). Instead, chronic stimulation of TLR9 with
unmethylated CpG oligonucleotides was found to be
unique in triggering the syndrome. Interestingly, dsDNA
viruses, like EBV, HCMV, MCMV and other herpesvi-
ruses, notoriously linked to active HLH episodes [46], acti-
vate TLR9 signaling during acute infection. Excessive
TLR9 triggering has also been linked to the development
of HLH in a second mouse model [47]. In another model
of secondary HLH, using IL-6 transgenic mice, an exag-
gerated response to TLR stimulation with Poly(I:C) as well
as with CpG was observed, but no HLH-like syndrome
developed. Solely injection with lipopolysaccharide (LPS),
a TLR4 ligand, induced an acute HLH phenotype in the
IL-6 transgenic mice, possibly mirroring the syndrome of
bacteria-induced HLH [48].
The role of immune-mediated pathology was further ex-
amined by treating MCMV-infected BALB/c mice with an
immunosuppressant. The steroid dexamethasone was
chosen, considering its preferred use in the HLH-2004
therapeutic guidelines [29]. Although dexamethasone was
not able to cure the mice, it did reduce the extent of
anemia and thrombocytopenia post infection and inhib-
ited the increase in plasma sCD25. Combined with the
findings from the cidofovir experiments, it appears that
the development of cytopenias and elevated sCD25 levels
are mostly immune-mediated. Indeed, it is known that
during systemic inflammatory reactions, i.e. following viral
infection, LPS administration or injection with proinflam-
matory cytokines, platelets are attracted to the liver and/
or lungs, where they accumulate, decreasing their num-
bers in peripheral blood and resulting in
thrombocytopenia [49, 50]. Liver platelet accumulation
has also been described in response to replication-
deficient, non-cytolytic adenoviruses, demonstrating the
immunological nature of the process [51]. Likely, anemia
also results from excessive immune activation and the
cytokine storm. Many HLH-related and MCMV-induced
cytokines are known to suppress hematopoiesis, amongst
which IL-1β, IFN-γ and TNF-α [52], whereas IL-6 has the
potency to specifically induce anemia [53]. However, as
the anemia developed acutely post infection, decreased
erythropoiesis is probably not the main cause, but rather
increased consumption and destruction of erythrocytes in
the inflammatory response [54], a process termed “con-
sumptive anemia of inflammation” [55]. Lastly, plasma
sCD25 has been shown to be shed by hyperactivated CD8
+ T cells [56] and is thought to reflect the degree of T cell
activation in HLH, suggesting an immunological back-
ground for this symptom as well.
Immunosuppressive treatment has been examined in
other animal models of HLH. In a humanized, transgenic
mouse model of secondary HLH, treatment with
dexamethasone or intravenous immunoglobulins did not
succeed to save the mice from fatal HLH [57], in line with
our findings using dexamethasone. In the LCMV-infected
perforin-deficient mouse model, dexamethasone therapy
was not successful either, nor was chemotherapeutic treat-
ment with cisplatin, clofarabine, doxorubicin, fludarabine,
5-fluorouracil or vinblastine [58]. Only etoposide, cyclo-
phosphamide and methotrexate, all agents proposed in
the HLH-2004 therapeutic protocol, substantially allevi-
ated symptoms and allowed survival of the LCMV-
infected perforin-deficient mice [58]. Thus, although dexa-
methasone was inadequate in the MCMV-induced mouse
model, other immunosuppressive agents may have a more
potent effect and may further unravel the role of immuno-
pathology in virus-associated secondary HLH.
Conclusions
Our data demonstrate that infectious viral titers do not
correlate with the severity of key HLH features, although
the titer is the highest in mouse strains developing an
HLH-like syndrome post MCMV infection. Lytic viral
replication and sustained viremia played an essential part
in the pathogenesis since abortive viral infection and
extracellular stimulation of pathogen receptors by
MCMV-specific antigens was insufficient to induce a full-
blown HLH-like syndrome. Nonetheless, a limited set of
symptoms, in particular anemia, thrombocytopenia and
elevated soluble CD25, appeared less dependent of the
viral replication but rather immune-mediated, as corrobo-
rated by immunosuppressive treatment of infected mice
with dexamethasone. Thus, distinguishing the pathogenic
effects of the virus itself from the immunological conse-
quences of viremia is not straightforward. Most likely, a
certain level of viremia is necessary to elicit the aberrant
immune responses driving HLH pathogenesis. Therefore,
in clinical practice, it remains equally important to halt
the rampant immune system and to eliminate persisting
infections by applying a combined treatment of immuno-
chemotherapy and supportive pathogen-directed therapy.
Case reports of patients with virus-associated HLH con-
firm that monotherapy with antivirals is usually insuffi-
cient to cure full-blown HLH [3, 6, 59].
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